Alpha-6-containing neuronal nicotinic acetylcholine receptor (α6* nAChR)

Alpha-6-containing neuronal nicotinic acetylcholine receptors (α6* nAChRs) are a specialized subtype of pentameric ligand-gated ion channels primarily expressed in the catecholaminergic nuclei of the brain, including the substantia nigra and ventral tegmental area. These receptors play a critical role in regulating the release of dopamine in the striatum and nucleus accumbens, making them central to the brain's reward and motor control systems. Due to their highly restricted localization on dopaminergic terminals, they are significant targets for treating neurodegenerative and psychiatric conditions. In Parkinson's disease, the loss of α6* nAChRs is closely correlated with the degeneration of dopaminergic neurons, suggesting that agonists or positive allosteric modulators could provide neuroprotective or symptomatic benefits. Furthermore, these receptors are heavily implicated in the reinforcing effects of nicotine and alcohol, positioning them as key targets for smoking cessation and addiction therapies. While selective pharmacological targeting remains challenging due to high structural homology with other nicotinic subtypes, research into selective antagonists like alpha-conotoxins and novel allosteric modulators continues to advance their therapeutic potential.

Other names

CHRNA6Alpha-6 nicotinic receptorAlpha-6-beta-2-beta-3 nAChRAlpha-6-beta-2 nAChRAlpha-6-containing nAChR

Agonist, Partial agonist, Antagonist, Positive allosteric modulator